Key challenges in immunotherapy for AML

Anthony Stein, MD, City Of Hope, Duarte, CA, discusses important advances and hurdles in immunotherapy for acute myeloid leukemia (AML), commenting on targeting CD47, the need to find novel treatment targets, and challenges in toxicity with CAR-T and NK-cell therapies for AML. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.